Discovery of a novel FAK inhibitor, NVP-TAE226, and its activities on in vivo and in vitro models

被引：1
|
作者：
Kawahara, E.
Yamaura, T.
Ohmori, O.
Nonomura, K.
Murakami, Y.
Niwa, S.
Meyer, T.
Mestan, J.
Honda, T.
Hatakeyama, S.
机构：
[1] Novartis Inst Biomed Res, Grobal Discovery Chem, Tsukuba, Ibaraki, Japan
[2] Novartis Inst Biomed Res, Discovery Biol, Tsukuba, Ibaraki, Japan
[3] Novartis Inst Biomed Res, Autoimmunity & Transplant, Vienna, Austria
[4] Novartis Inst Biomed Res, Expert Platform Kinase, Basel, Switzerland
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70566-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
561
引用
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [21] Effect of a novel FAK inhibitor targeted to the binding site of VEGFR3 on pancreatic cancer proliferation in vitro and in vivo
    Kurenova, E. V.
    Liao, J.
    He, D.
    Hunt, D. L.
    Chekhau, A.
    Hochwald, S. N.
    Ostrov, D. A.
    Cance, W. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [22] Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities
    Yao, Yiwu
    Tu, Zhengchao
    Liao, Chenzhong
    Wang, Zhen
    Li, Shang
    Yao, Hequan
    Li, Zheng
    Jiang, Sheng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (19) : 7672 - 7680
  • [23] Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
    Chang, Kwang-Yu
    Tsai, Shan-Yin
    Wu, Ching-Ming
    Yen, Chia-Jui
    Chuang, Bin-Fay
    Chang, Jang-Yang
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 7116 - 7126
  • [24] VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo
    Tam, Winnie F.
    Ring, Jennifer E.
    Trombino, Anthony F.
    Weaver, David T.
    Pachter, Jonathan A.
    Padval, Mahesh
    Xu, Qunli
    [J]. BLOOD, 2014, 124 (21)
  • [25] In Vitro and In Vivo Activities of TP0480066, a Novel Topoisomerase Inhibitor, against Neisseria gonorrhoeae
    Masuko, Aiko
    Takata, Iichiro
    Fujita, Kiyoko
    Okumura, Hirotoshi
    Ushiyama, Fumihito
    Amada, Hideaki
    Sugiyama, Hiroyuki
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)
  • [26] In vitro and in vivo antitumor activities of the dual PI3K/mTor inhibitor NVP-BEZ235. Implications for patient stratification strategies
    Maira, Michel
    Brachmann, Saskia
    Fritsch, Christine
    Hofmann, Irmgard
    Schnell, Christian
    Garcia-Echeverria, Carlos
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [27] In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas
    Martinho, Olga
    Silva-Oliveira, Renato
    Miranda-Goncalves, Vera
    Clara, Carlos
    Almeida, Jose Reynaldo
    Carvalho, Andre Lopes
    Barata, Joao Taborda
    Reis, Rui Manuel
    [J]. TRANSLATIONAL ONCOLOGY, 2013, 6 (02): : 187 - U264
  • [28] A novel salvianolic acid A analog with resveratrol structure and its antioxidant activities in vitro and in vivo
    Qiu, Jin-Mei
    Qin, Chang-Feng
    Wu, Shen-Gen
    Ji, Tong-Ying
    Tang, Guo-Tao
    Lei, Xiao-Yong
    Cao, Xuan
    Xie, Zhi-Zhong
    [J]. DRUG DEVELOPMENT RESEARCH, 2021, 82 (01) : 108 - 114
  • [29] Characterization of a novel polysaccharide from Arca subcrenata and its immunoregulatory activities in vitro and in vivo
    Shi, Hui
    Li, Jianhuan
    Liu, Fei
    Bi, Sixue
    Huang, Weijuan
    Luo, Yuanyuan
    Zhang, Man
    Song, Liyan
    Yu, Rongmin
    Zhu, Jianhua
    [J]. FOOD & FUNCTION, 2023, 14 (02) : 822 - 835
  • [30] Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models
    Lu, Xing
    Liu, Yan-Cheng
    Orvig, Chris
    Liang, Hong
    Chen, Zhen-Feng
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 181
12345